Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.
Nuesch R, Ananworanich J, Sirivichayakul S, Ubolyam S, Siangphoe U, Hill A, Cooper D, Lange J, Phanuphak P, Ruxrungtham K. Nuesch R, et al. Among authors: siangphoe u. Clin Infect Dis. 2005 Mar 1;40(5):728-34. doi: 10.1086/427878. Epub 2005 Feb 4. Clin Infect Dis. 2005. PMID: 15714420 Clinical Trial.
Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children.
Ananworanich J, Kosalaraksa P, Hill A, Siangphoe U, Bergshoeff A, Pancharoen C, Engchanil C, Ruxrungtham K, Burger D; HIV-NAT 017 Study Team. Ananworanich J, et al. Among authors: siangphoe u. Pediatr Infect Dis J. 2005 Oct;24(10):874-9. doi: 10.1097/01.inf.0000180578.38584.da. Pediatr Infect Dis J. 2005. PMID: 16220084 Clinical Trial.
Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012).
Boyd MA, Dixit NM, Siangphoe U, Buss NE, Salgo MP, Lange JM, Phanuphak P, Cooper DA, Perelson AS, Ruxrungtham K. Boyd MA, et al. Among authors: siangphoe u. J Infect Dis. 2006 Nov 1;194(9):1319-22. doi: 10.1086/508291. Epub 2006 Sep 25. J Infect Dis. 2006. PMID: 17041859 Clinical Trial.
Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, Mahanontharit A, Ubolyam S, Cooper D, Phanuphak P, Ruxrungtham K. Ananworanich J, et al. Among authors: siangphoe u. J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):523-9. J Acquir Immune Defic Syndr. 2005. PMID: 16044002 Clinical Trial.
A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
Ananworanich J, Hill A, Siangphoe U, Ruxrungtham K, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Nuesch R, Cooper DA, Hirschel B; Staccato Study Group. Ananworanich J, et al. Among authors: siangphoe u. Antivir Ther. 2005;10(6):761-7. Antivir Ther. 2005. PMID: 16218176 Clinical Trial.
HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Puthanakit T, Jourdain G, Hongsiriwon S, Suntarattiwong P, Chokephaibulkit K, Sirisanthana V, Kosalaraksa P, Petdachai W, Hansudewechakul R, Siangphoe U, Suwanlerk T, Ananworanich J; HIV-NAT 086Study Team. Puthanakit T, et al. Among authors: siangphoe u. HIV Med. 2010 Oct 1;11(9):565-72. doi: 10.1111/j.1468-1293.2010.00828.x. Epub 2010 Mar 25. HIV Med. 2010. PMID: 20345882 Free article.
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
Ungsedhapand C, Srasuebkul P, Cardiello P, Ruxrungtham K, Ratanasuwan W, Kroon ED, Tongtalung M, Juengprasert N, Ubolyam S, Siangphoe U, Emery S, Lange JM, Cooper DA, Phanuphak P; HIV-NAT 002 and HIV-NAT 003 Study Team. Ungsedhapand C, et al. Among authors: siangphoe u. J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):693-701. doi: 10.1097/00126334-200406010-00006. J Acquir Immune Defic Syndr. 2004. PMID: 15167288 Clinical Trial.
50 results